

10/634289

=> d his

(FILE 'HOME' ENTERED AT 15:36:40 ON 08 JAN 2005)

FILE 'REGISTRY' ENTERED AT 15:36:56 ON 08 JAN 2005

L1 STRUCTURE UPLOADED
L2 1 S L1
L3 STRUCTURE UPLOADED
L4 1 S L3
L5 STRUCTURE UPLOADED
L6 2 S L5
L7 STRUCTURE UPLOADED
L8 6 S L7
L9 1268 S L7 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:50:02 ON 08 JAN 2005

L10 2 S L9
L11 0 S L10 NOT ISOQUINOLIN?
E BUNKER AMY/IN
L12 11 S E3-E5
L13 1 S L12 AND AZAISOQUINOLIN?
L14 STRUCTURE UPLOADED
S L14

FILE 'REGISTRY' ENTERED AT 16:06:11 ON 08 JAN 2005

L15 1 S L14

FILE 'CAPLUS' ENTERED AT 16:06:12 ON 08 JAN 2005

L16 1 S L15

FILE 'REGISTRY' ENTERED AT 16:06:35 ON 08 JAN 2005

L17 1 S L16 NOT L10
L18 1268 S L9 NOT L15
L19 69 S L14 SSS FULL









FILE 'CAPLUS' ENTERED AT 16:08:37 ON 08 JAN 2005

L20 2 S L19

FILE 'BEILSTEIN' ENTERED AT 16:09:47 ON 08 JAN 2005

L21 0 S L14
L22 0 S L14 SSS FULL

=>



chain nodes :

13 14 15 16 17 18 19 20 21 22 23 24 26 27 28 29 30 31 42 43 46 47

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

3-42 7-47 8-46 13-14 15-16 16-17 18-19 20-21 21-22 23-24 26-27 28-29 30-31
42-43

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

1-2 1-6 2-3 3-4 3-42 4-5 5-6 6-10 7-47 8-9 8-46 9-10 13-14 15-16 16-17 18-19
20-21 21-22 23-24 26-27 28-29 30-31 42-43

exact bonds :

5-7 7-8

isolated ring systems :

containing 1 :

G1:C,N

G2:C,O,S,N

G3:[*1-*2],[*3-*4],[*5-*6],[*7-*8],[*9-*10]





Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 13:CLASS
14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 26:CLASS 27:Atom 28:CLASS 29:CLASS 30:CLASS 31:CLASS 42:CLASS
43:Atom 46:CLASS 47:CLASS

10/634289

Uploading C:\STNEXP4\QUERIES\1034289d.str

L14



chain nodes :

14 16 17 18 19 20 21 22 23 24 25 26 36

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

3-36 7-16 14-36 17-18 17-23 19-20 20-24 21-22 25-26

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

1-2 1-6 2-3 3-4 3-36 4-5 5-6 6-10 7-16 8-9 9-10 14-36 17-18 17-23 19-20
20-24 21-22 25-26

exact bonds :

5-7 7-8

isolated ring systems :

containing 1 :

G1:C,N

G2:C,O,S,N

G3:[*1-*2],[*3-*4],[*5-*6],[*7-*8]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

14:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

25:CLASS 26:CLASS 36:CLASS

10/634289

=> d 1-2 bib abs hitstr


L20 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:143113 CAPLUS
DN 140:175191
TI Azaisoquinoline derivatives as matrix metalloproteinase inhibitors,
pharmaceutical compositions, and therapeutic use
IN Bunker, Amy Mae; Picard, Joseph Armand
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014866	A1	20040219	WO 2003-IB3485	20030804
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004038961	A1	20040226	US 2003-634289	20030805
PRAI	US 2002-403219P	P	20020813		
OS	MARPAT 140:175191				

AB The invention provides azaisoquinoline derivs., or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compns. comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering a compound of the invention, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods for treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of the invention, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component.


IT 658036-97-6 658036-98-7 658036-99-8
658037-00-4 658037-01-5 658037-02-6
658037-03-7 658037-04-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(azaisoquinoline derivs. as matrix metalloproteinase inhibitors, pharmaceutical compns., and therapeutic use)

RN 658036-97-6 CAPLUS
CN 1,6-Naphthyridin-5(6H)-one, 3-(3-phenyl-1-propynyl)-6-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 658036-98-7 CAPLUS
CN 1,6-Naphthyridin-5(6H)-one, 6-[(3-fluorophenyl)methyl]-3-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)

10/634289




RN 658036-99-8 CAPLUS

CN Benzoic acid, 4-[[3-[3-(1H-imidazol-1-yl)-1-propynyl]-5-oxo-1,6-naphthyridin-6(5H)-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 658037-00-4 CAPLUS

CN Benzoic acid, 4-[[3-[3-(1H-imidazol-1-yl)-1-propynyl]-5-oxo-1,6-naphthyridin-6(5H)-yl]methyl]- (9CI) (CA INDEX NAME)




RN 658037-01-5 CAPLUS

CN Benzonitrile, 3-[[[1-oxo-7-(3-phenyl-1-propynyl)-2,6-naphthyridin-2(1H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 658037-02-6 CAPLUS


CN Benzenesulfonamide, 4-[[[1-oxo-7-(3-phenyl-1-propynyl)-2,6-naphthyridin-2(1H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 658037-03-7 CAPLUS


CN Benzoic acid, 4-[[[1-oxo-7-[3-(1H-1,2,3-triazol-1-yl)-1-propynyl]-2,6-naphthyridin-2(1H)-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/634289



RN 658037-04-8 CAPLUS

CN Benzoic acid, 4-[[1-oxo-7-[3-(1H-1,2,3-triazol-1-yl)-1-propynyl]-2,6-naphthyridin-2(1H)-yl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:142962 CAPLUS

DN 140:181338

TI Preparation of isoquinoline derivatives as matrix metalloproteinase inhibitors

IN Bunker, Amy Mae; Ortwine, Daniel Fred

PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl., 189 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014379	A1	20040219	WO 2003-IB3521	20030804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2004044000 A1 20040304 US 2003-634473 20030805 PRAI US 2002-403031P P 20020813 OS MARPAT 140:181338 GI				




AB This invention provides compds. defined by formula (I) or pharmaceutically acceptable salts thereof [R1 = each (un)substituted C5 or C6 cycloalkyl-C1-6 alkylenyl, C8-10 bicycloalkyl-C1-8 alkylenyl, 5- or 6-membered heterocycloalkyl-C1-5 alkylenyl, 8- to 10-membered heterobicycloalkyl-C1-5 alkylenyl, phenyl-C1-8 alkylenyl, naphthyl-C1-8 alkylenyl, naphthyl-C1-8 alkylenyl, 5- or 6-membered heteroaryl-C1-8 alkylenyl, 8- to 10-membered heterobiaryl-C1-8 alkylenyl, Ph, naphthyl, etc.; R2 = H, C1-6 alkyl, each (un)substituted phenyl-C1-8 alkylenyl, naphthyl-C1-8 alkylenyl, 5- or 6-membered heteroaryl-C1-8 alkylenyl, or 8-

to 10-membered heterobiaryl-C1-8 alkylenyl, etc.; R3, R4 = H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-8 alkylenyl, Ph, phenyl-C1-8 alkylenyl, naphthyl, naphthyl-C1-8 alkylenyl, 3- to 6-membered heterocycloalkyl, or 3- to 6-membered heterocycloalkyl-C1-8 alkylenyl, HO; C1-6 alkoxy, NH2, mono- or di(C1-6 alkyl)amino; R5 = H, C1-6 alkyl, NH2, HO, halo; n = an integer of 0-3; Q = OC(O), CH(R6)C(O), OC(NR6), CH(R6)C(NR6), N(R6)C(O), N(R6)C(S), N(R6)C(NR6), N(R6)CH2, SC(O), CH(R6)C(S), SC(NR6), trans- or cis-HC:CH, C.tplbond.C, CH2C.tplbond.C, C.tplbond.CCH2, etc.; R6 = H, C1-6 alkyl, C3-6 cycloalkyl, Ph, benzyl, etc.; Y = CO, CH2,CH(R7), C(R7)2, O, S, S(O), S(O)2; R7 = C1-6 alkyl, NH2, HO, halo]. The invention also provides pharmaceutical compns. comprising the compound I and the use of the compds. I for the manufacture of a medicament useful for treating osteoarthritis or rheumatoid arthritis. Thus, 4-(7-bromo-1-oxo-1H-isoquinolin-2-ylmethyl)benzoic acid tert-Bu ester was coupled with 3-phenyl-1-propyne in the presence of CuI and Pd(Ph3P)4 in DMF at 65° for 5 h, followed by treatment with CF3CO2H to give 4-[1-oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-ylmethyl]benzoic acid (II). II showed IC50 of 0.0018 µM against MMP-13 catalytic domain.

IT 658081-94-8P, 4-[[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzoic acid tert-butyl ester
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate; preparation of isoquinoline derivs. as matrix metalloproteinase inhibitors for treating osteoarthritis or rheumatoid arthritis)

RN 658081-94-8 CAPLUS


CN Benzoic acid, 4-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 658082-21-4P, 4-[[7-[3-(Imidazol-1-yl)prop-1-ynyl]-1-oxo-1H-isoquinolin-2-yl]methyl]benzoic acid tert-butyl ester 658082-25-8P, 4-[[1-Oxo-7-[3-((1,2,4)triazol-1-yl)prop-1-ynyl]-1H-isoquinolin-2-yl]methyl]benzoic acid tert-butyl ester 658082-27-0P, 4-[[4-Methyl-1-oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzoic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of isoquinoline derivs. as matrix metalloproteinase inhibitors for treating osteoarthritis or rheumatoid arthritis)


RN 658082-21-4 CAPLUS

CN Benzoic acid, 4-[[7-[3-(1H-imidazol-1-yl)-1-propynyl]-1-oxo-2(1H)-isoquinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 658082-25-8 CAPLUS

CN Benzoic acid, 4-[[1-oxo-7-[3-(1H-1,2,4-triazol-1-yl)-1-propynyl]-2(1H)-isoquinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 658082-27-0 CAPLUS

CN Benzoic acid, 4-[[4-methyl-1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 658081-96-0P, 4-[[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzoic acid 658081-97-1P, 7-(3-Phenylprop-1-ynyl)-2-(4-trifluoromethylbenzyl)-2H-isoquinolin-1-one 658081-99-3P, 2-(3-Fluorobenzyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658082-01-0P, 3-[[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzonitrile 658082-03-2P, 4-[[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzenesulfonamide 658082-05-4P, 4-[[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzoic acid methyl ester 658082-07-6P, 3-[[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzoic acid methyl ester 658082-09-8P, 2-(4-Fluorobenzyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658082-11-2P, 7-(3-Phenylprop-1-ynyl)-2-(3-trifluoromethylbenzyl)-2H-isoquinolin-1-one 658082-13-4P, 2-(3-Chlorobenzyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658082-15-6P, 2-(3,4-Difluorobenzyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658082-17-8P, 2-(3,5-Difluoro-4-hydroxybenzyl)-7-[3-(4H-[1,2,3]triazol-4-yl)prop-1-ynyl]-2H-isoquinolin-1-one 658082-23-6P, 4-[[7-[3-(Imidazol-1-yl)prop-1-ynyl]-1-oxo-1H-isoquinolin-2-yl]methyl]benzoic acid trifluoroacetate 658082-24-7P, 4-[[1-Oxo-7-(3-[[1,2,3]triazol-1-yl)prop-1-ynyl]-1H-isoquinolin-2-yl]methyl]benzoic acid tert-butyl ester 658082-26-9P, 4-[[1-Oxo-7-(3-[[1,2,4]triazol-1-yl)prop-1-ynyl]-1H-isoquinolin-2-yl]methyl]benzoic acid 658082-31-6P, 4-[[4-Methyl-1-oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzoic acid 658082-32-7P, 7-(3-Phenylprop-1-ynyl)-2-(4-(2H-tetrazol-5-yl)benzyl)-2H-isoquinolin-1-one 658082-35-0P, 4-[[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]-N-(piperidin-1-yl)benzamide 658082-36-1P, N-[2-(Morpholin-4-yl)ethyl]-4-[[1-oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzamide 658082-37-2P, N-(5-Oxo-4,5-dihydro-1H-pyrazol-3-yl)-4-[[1-oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]benzamide 658083-00-2P, 7-(3-Phenylprop-1-ynyl)-2-[(tetrahydropyran-2-yl)methyl]-2H-isoquinolin-1-one 658083-01-3P, 2-[3-Hydroxy-2,2-bis(hydroxymethyl)propyl]-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-02-4P, 3-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]propionitrile 658083-03-5P, 2-(2,3-Dihydroxypropyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-04-6P, 2-[2-(1,3-Dioxolan-2-yl)ethyl]-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-05-7P, 4-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]butyronitrile 658083-06-8P, 2-(2-Methyltetrahydropyran-3-yl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-07-9P, 2-(2,2-Dimethoxyethyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-08-0P, 7-(3-Phenylprop-1-ynyl)-2-[(tetrahydrofuran-2-yl)methyl]-2H-isoquinolin-1-one 658083-09-1P, 5-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]pentanenitrile 658083-10-4P, 3-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]propionic acid methyl ester 658083-11-5P, Acetic acid 4-[1-oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]butyl ester 658083-12-6P, 2-[2-(1,3-Dioxolan-2-yl)ethyl]-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-13-7P, 2-(1,3-Dioxolan-2-yl)methyl-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one


658083-14-8P, 2-[4-(Methanesulfonyl)benzyl]-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-15-9P, 5-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]pentanoic acid methyl ester 658083-16-0P, [1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]acetic acid methyl ester 658083-17-1P, 2-(2,2-Diethoxyethyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-18-2P, 5-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]pentanoic acid ethyl ester 658083-19-3P, 3-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]propionic acid ethyl ester 658083-20-6P, 7-Methoxy-3-[[1-oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]methyl]-1,4-benzoxazin-2-one 658083-21-7P, 6-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]hexanoic acid ethyl ester 658083-22-8P, 2-(2-Methoxyethyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-23-9P, [1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]acetic acid ethyl ester 658083-24-0P, 2-(3-Hydroxy-2,2-dimethylpropyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-25-1P, 2-[2-(Benzenesulfinyl)ethyl]-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-26-2P, 4-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]butyric acid ethyl ester 658083-27-3P, 2-(2-Oxobutyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-28-4P, 2-[2-(6-Hydroxyhexyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-29-5P, 2-Benzenesulfonylmethyl-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-30-8P, 2-(3,3-Dimethyl-2-oxobutyl)-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-31-9P, 6-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]hexanenitrile 658083-32-0P, 2-Benzyl-7-(3-phenylprop-1-ynyl)-2H-isoquinolin-1-one 658083-33-1P, 7-(3-Phenylprop-1-ynyl)-2-(2,2,2-trifluoroethyl)-2H-isoquinolin-1-one 658083-34-2P, 7-(3-Phenylprop-1-ynyl)-2-(4,4,4-trifluorobutyl)-2H-isoquinolin-1-one 658083-35-3P, 7-[1-Oxo-7-(3-phenylprop-1-ynyl)-1H-isoquinolin-2-yl]heptanenitrile

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoquinoline derivs. as matrix metalloproteinase inhibitors for treating osteoarthritis or rheumatoid arthritis)


RN 658081-96-0 CAPLUS

CN Benzoic acid, 4-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 658081-97-1 CAPLUS

CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 658081-99-3 CAPLUS


CN 1(2H)-Isoquinolinone, 2-[(3-fluorophenyl)methyl]-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



10/634289


RN 658082-01-0 CAPLUS

CN Benzonitrile, 3-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 658082-03-2 CAPLUS

CN Benzenesulfonamide, 4-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 658082-05-4 CAPLUS

CN Benzoic acid, 4-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 658082-07-6 CAPLUS

CN Benzoic acid, 3-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 658082-09-8 CAPLUS


CN 1(2H)-Isoquinolinone, 2-[(4-fluorophenyl)methyl]-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 658082-11-2 CAPLUS


CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

10/634289




RN 658082-13-4 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(3-chlorophenyl)methyl]-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)




RN 658082-15-6 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(3,4-difluorophenyl)methyl]-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 658082-17-8 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[(3,5-difluoro-4-hydroxyphenyl)methyl]-7-[3-(4H-1,2,3-triazol-4-yl)-1-propynyl]- (9CI) (CA INDEX NAME)




RN 658082-23-6 CAPLUS

CN Benzoic acid, 4-[[7-[3-(1H-imidazol-1-yl)-1-propynyl]-1-oxo-2(1H)-isoquinolinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 658082-22-5


CMF C23 H17 N3 O3




CM 2

10/634289


CRN 76-05-1
CMF C2 H F3 O2




RN 658082-24-7 CAPLUS
CN Benzoic acid, 4-[[1-oxo-7-[3-(1H-1,2,3-triazol-1-yl)-1-propynyl]-2(1H)-isoquinolinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 658082-26-9 CAPLUS
CN Benzoic acid, 4-[[1-oxo-7-[3-(1H-1,2,4-triazol-1-yl)-1-propynyl]-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 658082-31-6 CAPLUS
CN Benzoic acid, 4-[[4-methyl-1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 658082-32-7 CAPLUS
CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-[[4-(1H-tetrazol-5-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 658082-35-0 CAPLUS
CN Benzamide, 4-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]-N-1-piperidinyl- (9CI) (CA INDEX NAME)

10/634289




RN 658082-36-1 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 658082-37-2 CAPLUS

CN Benzamide, N-(4,5-dihydro-5-oxo-1H-pyrazol-3-yl)-4-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 658083-00-2 CAPLUS

CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-[(tetrahydro-2H-pyran-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 658083-01-3 CAPLUS


CN 1(2H)-Isoquinolinone, 2-[3-hydroxy-2,2-bis(hydroxymethyl)propyl]-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 658083-02-4 CAPLUS


CN 2(1H)-Isoquinolinepropanenitrile, 1-oxo-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)

10/634289




RN 658083-03-5 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(2,3-dihydroxypropyl)-7-(3-phenyl-1-propynyl)-
(9CI) (CA INDEX NAME)




RN 658083-04-6 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[2-(1,3-dioxan-2-yl)ethyl]-7-(3-phenyl-1-propynyl)-
(9CI) (CA INDEX NAME)




RN 658083-05-7 CAPLUS

CN 2(1H)-Isoquinolinebutanenitrile, 1-oxo-7-(3-phenyl-1-propynyl)- (9CI) (CA
INDEX NAME)




RN 658083-06-8 CAPLUS

CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-(tetrahydro-2-methyl-2H-
pyran-3-yl)- (9CI) (CA INDEX NAME)



RN 658083-07-9 CAPLUS


CN 1(2H)-Isoquinolinone, 2-(2,2-dimethoxyethyl)-7-(3-phenyl-1-propynyl)-
(9CI) (CA INDEX NAME)



10/634289


RN 658083-08-0 CAPLUS

CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 658083-09-1 CAPLUS

CN 2(1H)-Isoquinolinepropanenitrile, 1-oxo-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)




RN 658083-10-4 CAPLUS

CN 2(1H)-Isoquinolinepropanoic acid, 1-oxo-7-(3-phenyl-1-propynyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 658083-11-5 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[4-(acetyloxy)butyl]-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 658083-12-6 CAPLUS


CN 1(2H)-Isoquinolinone, 2-[2-(1,3-dioxolan-2-yl)ethyl]-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 658083-13-7 CAPLUS


CN 1(2H)-Isoquinolinone, 2-(1,3-dioxolan-2-ylmethyl)-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)

10/634289




RN 658083-14-8 CAPLUS

CN 1(2H)-Isoquinolinone, 2-[[4-(methylsulfonyl)phenyl]methyl]-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)




RN 658083-15-9 CAPLUS

CN 2(1H)-Isoquinolinepentanoic acid, 1-oxo-7-(3-phenyl-1-propynyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 658083-16-0 CAPLUS

CN 2(1H)-Isoquinolineacetic acid, 1-oxo-7-(3-phenyl-1-propynyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 658083-17-1 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(2,2-diethoxyethyl)-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 658083-18-2 CAPLUS


CN 2(1H)-Isoquinolinepentanoic acid, 1-oxo-7-(3-phenyl-1-propynyl)-, ethyl ester (9CI) (CA INDEX NAME)



10/634289


RN 658083-19-3 CAPLUS

CN 2(1H)-Isoquinolinepropanoic acid, 1-oxo-7-(3-phenyl-1-propynyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 658083-20-6 CAPLUS

CN 2H-1,4-Benzoxazin-2-one, 7-methoxy-3-[[1-oxo-7-(3-phenyl-1-propynyl)-2(1H)-isoquinolinyl]methyl]- (9CI) (CA INDEX NAME)




RN 658083-21-7 CAPLUS

CN 2(1H)-Isoquinolinehexanoic acid, 1-oxo-7-(3-phenyl-1-propynyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 658083-22-8 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(2-methoxyethyl)-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 658083-23-9 CAPLUS


CN 2(1H)-Isoquinolineacetic acid, 1-oxo-7-(3-phenyl-1-propynyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 658083-24-0 CAPLUS


CN 1(2H)-Isoquinolinone, 2-(3-hydroxy-2,2-dimethylpropyl)-7-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)

10/634289




RN 658083-25-1 CAPLUS

CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-[2-(phenylsulfinyl)ethyl]-
(9CI) (CA INDEX NAME)




RN 658083-26-2 CAPLUS

CN 2(1H)-Isoquinolinebutanoic acid, 1-oxo-7-(3-phenyl-1-propynyl)-, ethyl
ester (9CI) (CA INDEX NAME)




RN 658083-27-3 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(2-oxobutyl)-7-(3-phenyl-1-propynyl)- (9CI) (CA
INDEX NAME)




RN 658083-28-4 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(6-hydroxyhexyl)-7-(3-phenyl-1-propynyl)- (9CI)
(CA INDEX NAME)



RN 658083-29-5 CAPLUS


CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-[(phenylsulfonyl)methyl]-
(9CI) (CA INDEX NAME)



10/634289


RN 658083-30-8 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(3,3-dimethyl-2-oxobutyl)-7-(3-phenyl-1-propynyl)-
(9CI) (CA INDEX NAME)




RN 658083-31-9 CAPLUS

CN 1(2H)-Isoquinolinehexanenitrile, 1-oxo-7-(3-phenyl-1-propynyl)- (9CI) (CA
INDEX NAME)




RN 658083-32-0 CAPLUS

CN 1(2H)-Isoquinolinone, 2-(phenylmethyl)-7-(3-phenyl-1-propynyl)- (9CI) (CA
INDEX NAME)




RN 658083-33-1 CAPLUS

CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-(2,2,2-trifluoroethyl)-
(9CI) (CA INDEX NAME)



RN 658083-34-2 CAPLUS


CN 1(2H)-Isoquinolinone, 7-(3-phenyl-1-propynyl)-2-(4,4,4-trifluorobutyl)-
(9CI) (CA INDEX NAME)



RN 658083-35-3 CAPLUS

CN 2(1H)-Isoquinolineheptanenitrile, 1-oxo-7-(3-phenyl-1-propynyl)- (9CI)
(CA INDEX NAME)

10/634289



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/634289

=> d 110 bib abs

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:615576 CAPLUS

DN 137:169431

TI Preparation of isoquinolinones as dipeptidyl peptidase IV inhibitors for the prophylaxis or treatment of diabetes

IN Oi, Satoru; Ikedou, Koji; Takeuchi, Koji; Ogino, Masaki; Banno, Yoshihiro; Tawada, Hiroyuki; Yamane, Taihei

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 600 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062764	A1	20020815	WO 2002-JP831	20020201
	WO 2002062764	C2	20021010		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2437492	AA	20020815	CA 2002-2437492	20020201
	JP 2003238566	A2	20030827	JP 2002-26185	20020201
	EP 1355886	A1	20031029	EP 2002-711278	20020201
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2002006831	A	20040706	BR 2002-6831	20020201
	NO 2003003385	A	20030930	NO 2003-3385	20030729
	US 2004082607	A1	20040429	US 2003-470805	20030801
PRAI	JP 2001-27349	A	20010202		
	JP 2001-292388	A	20010925		
	JP 2001-382232	A	20011214		
	WO 2002-JP831	W	20020201		
OS	MARPAT 137:169431				
GI					



III

AB Title compds. I [R1, R2 = (un)substituted alkyl or heterocyclic ring; A = (un)substituted 5 to 10-membered aromatic ring; X = bond, O, S, etc.; L = divalent hydrocarbon or a salt], their pharmaceutically acceptable salts and formulations were prepared. For example, acylation of amino isoquinolinone II, followed by BOC deprotection provided claimed isoquinolinone III.HCl. Isoquinolinone III inhibited human dipeptidyl peptidase V with an IC50 = 0.25 µM. Also, the plasma glucose-lowering (76%) and insulinotropic effects (255%) of III in rat were reported. Compds. I have superior peptidase inhibitory activity and are useful for the prophylaxis or treatment of diabetes.


10/634289

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l10 2 bib abs hitstr

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:152935 CAPLUS
DN 134:193349
TI Preparation and antimicrobial activities of combinatorial libraries of
4-unsubstituted dihydroisoquinolinone derivatives
IN Motesharei, Kianoush; Lebl, Michal; Krchnak, Viktor; Ni, Yidong
PA Trega Biosciences, Inc., USA
SO PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001014879	A1	20010301	WO 2000-US20774	20000728
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6452009	B1	20020917	US 1999-378569	19990819
	EP 1210598	A1	20020605	EP 2000-955287	20000728
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRAI	US 1999-378569	A	19990819		
	WO 2000-US20774	W	20000728		
OS	MARPAT 134:193349				
GI					



AB Dihydroisoquinolinones I [R1, R2 = H, alkyl, alkenyl, Ph, etc.; R3 = H, alkyl, heteroaryl, etc.; R4 = -, DWE and W = -, cycloalkylene, arylene, etc. and D and E = -, alkylene, alkynylene, etc.; R5 = -, O, S, amino; R6 = -, alkylene, alkenylene; R7 = H, halide, OR13, CO2R13, etc.; X, Y, Z = H, halo, OH, cyano, nitro, etc.; m, n, p = 0, 1 and when 0 the absent carbonyl can be replaced with SO2] were prepared. Thus, bromoacetic acid was coupled to a resin and the resulting compds. were coupled with 1,4-Boc-NH-CH2-Ph-COOH, deprotected, and reacted with an aldehyde. The resulting compds. were then reacted with 4-nitrohomophthalic acid, reduced with tin chloride, and the compds. were reacted with a carboxylic acid. The resulting compds. were then cleaved and extracted. The melanocortin receptor assay and antimicrobial activity of I were investigated.

IT 316794-00-0P 316794-18-0P 316794-26-0P
317837-21-1P 317860-47-2P 318282-92-7P
328058-84-0P 328058-89-5P 328058-90-8P
328058-92-0P 328059-00-3P 328059-01-4P
328059-17-2P 328059-20-7P 328059-26-3P
328059-27-4P 328059-28-5P 328059-31-0P
328059-35-4P 328059-40-1P 328059-50-3P
328059-51-4P 328059-59-2P 328059-60-5P
328059-63-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and antimicrobial activities of combinatorial libraries of dihydroisoquinolinones)

RN 316794-00-0 CAPLUS


CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-1-oxo-3-phenyl-7-[[[1-phenylcyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

10/634289




RN 316794-18-0 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[(4-iodobenzoyl)amino]-1-oxo-3-(2-quinolinyl)- (9CI) (CA INDEX NAME)




RN 316794-26-0 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[(4-iodobenzoyl)amino]-1-oxo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 317837-21-1 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-7-[(2-furanylcarbonyl)amino]-3,4-dihydro-3-(1-naphthalenyl)-1-oxo- (9CI) (CA INDEX NAME)




RN 317860-47-2 CAPLUS

CN Benzamide, N-(2-amino-2-oxoethyl)-4-[[7-[(2,6-difluorobenzoyl)amino]-3-[4-(1,1-dimethylethyl)phenyl]-3,4-dihydro-1-oxo-2(1H)-isoquinolinyl]methyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 318282-92-7 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-7-[[2-fluoro-3-(trifluoromethyl)benzoyl]amino]-3,4-dihydro-1-oxo-3-phenyl- (9CI) (CA INDEX NAME)




RN 328058-84-0 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-7-[[2-fluoro-3-(trifluoromethyl)benzoyl]amino]-3,4-dihydro-1-oxo-3-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 328058-89-5 CAPLUS


CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-3-(3,5-dimethoxyphenyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[[4-methylcyclohexyl]carbonyl]amino]-1-oxo- (9CI) (CA INDEX NAME)



RN 328058-90-8 CAPLUS


CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3-[4-[3-(dimethylamino)propoxy]phenyl]-3,4-dihydro-7-[[4-iodobenzoyl]amino]-1-oxo- (9CI) (CA INDEX NAME)

10/634289




RN 328058-92-0 CAPLUS

CN Benzamide, N-(2-amino-2-oxoethyl)-4-[[3-[[4-[3-(dimethylamino)propoxy]phenyl]-3,4-dihydro-1-oxo-7-[[4-(trifluoromethoxy)benzoyl]amino]-2(1H)-isoquinolinyl]methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 328059-00-3 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-3-(3,5-dimethoxyphenyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-1-oxo-7-[[4-(trifluoromethoxy)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 328059-01-4 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[[3,4-difluorobenzoyl]amino]-3-(3,5-dimethoxyphenyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)




RN 328059-17-2 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[[3,5-bis(trifluoromethyl)benzoyl]amino]-3-(3,4-difluorophenyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)




RN 328059-20-7 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[[3,5-bis(trifluoromethyl)benzoyl]amino]-N-[2-(dimethylamino)ethyl]-3,4-dihydro-3-(4-methylphenyl)-1-oxo- (9CI) (CA INDEX NAME)




RN 328059-26-3 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-3-(1-naphthalenyl)-1-oxo-7-[(pyrazinylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 328059-27-4 CAPLUS


CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-3-(1-naphthalenyl)-1-oxo-7-[[1-phenylcyclopropyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 328059-28-5 CAPLUS


CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-7-[[4-methyl-1,2,3-thiadiazol-5-yl]carbonyl]amino]-3-(1-naphthalenyl)-1-oxo- (9CI) (CA INDEX NAME)

10/634289




RN 328059-31-0 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3-[4-[3-(dimethylamino)propoxy]phenyl]-3,4-dihydro-7-[[4-methylcyclohexyl]carbonyl]amino]-1-oxo- (9CI) (CA INDEX NAME)




RN 328059-35-4 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-3-[4-[3-(dimethylamino)propoxy]phenyl]-3,4-dihydro-7-[[4-iodobenzoyl]amino]-1-oxo-N-[3-(trifluoromethyl)phenyl]methyl- (9CI) (CA INDEX NAME)




RN 328059-40-1 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[(3,4-difluorobenzoyl)amino]-N-[2-(dimethylamino)ethyl]-3-[4-(1,1-dimethylethyl)phenyl]-3,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)




RN 328059-50-3 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[(4-cyanobenzoyl)amino]-N-[2-(dimethylamino)ethyl]-3-[4-(1,1-dimethylethyl)phenyl]-3,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)




RN 328059-51-4 CAPLUS

2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3-[4-(1,1-dimethylethyl)phenyl]-3,4-dihydro-7-[[5-methylpyrazinyl]carbonyl]amino]-1-oxo- (9CI) (CA INDEX NAME)




RN 328059-59-2 CAPLUS

CN 2-[1H]-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-7-[[3,5-bis(trifluoromethyl)benzoyl]amino]-N-[2-(dimethylamino)ethyl]-3,4-dihydro-1-oxo-3-(2-quinoliny)- (9CI) (CA INDEX NAME)



RN 328059-60-5 CAPLUS


CN 2 (1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-N-[2-(dimethylamino)ethyl]-3-[4-(1,1-dimethylethyl)phenyl]-7-[(2-fluorobenzoyl)amino]-3,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)



RN 328059-63-8 CAPLUS

CN 2(1H)-Isoquinolinepropanamide, N-(2-amino-2-oxoethyl)-3-(3,5-dimethoxyphenyl)-N-[2-(dimethylamino)ethyl]-3,4-dihydro-1-oxo-7-[(2,3,5,6-tetrafluoro-4-methylbenzoyl)amino]- (9CI) (CA INDEX NAME)

10/634289



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

10/634289

> s e3-e5

1 "BUNKER AMY"/IN
2 "BUNKER AMY M"/IN
8 "BUNKER AMY MAE"/IN
L12 11 ("BUNKER AMY"/IN OR "BUNKER AMY M"/IN OR "BUNKER AMY MAE"/IN)

=> s l12 and azaisoquinolin?

1 AZAISOQUINOLIN?
L13 1 L12 AND AZAISOQUINOLIN?

=> d bib abs

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:143113 CAPLUS
DN 140:175191
TI Azaisoquinoline derivatives as matrix metalloproteinase
inhibitors, pharmaceutical compositions, and therapeutic use
IN Bunker, Amy Mae; Picard, Joseph Armand
PA Warner-Lambert Company LLC, USA
SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014866	A1	20040219	WO 2003-IB3485	20030804
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004038961	A1	20040226	US 2003-634289	20030805
PRAI	US 2002-403219P	P	20020813		

OS MARPAT 140:175191

AB The invention provides azaisoquinoline derivs., or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compns. comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering a compound of the invention, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods for treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of the invention, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d re

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
RE
(1) Eisai Co Ltd; EP 0722936 A 1996 CAPLUS
(2) Hayashizaki, Y; WO 0244195 A 2002 CAPLUS
(3) Univ Boston; WO 0196607 A 2001 CAPLUS

=>